Exhibit 3.1
FOURTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
CARIBOU BIOSCIENCES, INC.
(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)
Caribou Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”),
DOES HEREBY CERTIFY:
1. That the name of this corporation is Caribou Biosciences, Inc., and that this corporation was originally incorporated as a Delaware corporation on October 28, 2011.
2. That this Fourth Amended and Restated Certificate of Incorporation, which restates and integrates and also further amends the provisions of this corporation’s Third Amended and Restated Certificate of Incorporation, was duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law and by the written consent of the corporation’s stockholders in accordance with Section 228 of the General Corporation Law.
3. That the Third Amended and Restated Certificate of Incorporation of this corporation is hereby amended and restated in its entirety to read as follows:
FIRST: The name of this corporation is Caribou Biosciences, Inc. (the “Corporation”).
SECOND: The address of the Corporation’s registered office in the State of Delaware is 3500 South DuPont Highway, City of Dover, County of Kent, Delaware 19901. The name of the registered agent at such address is Incorporating Services, Ltd.
THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “General Corporation Law”).
FOURTH: The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is 38,930,622, comprised of: (i) 24,500,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”), and (ii) 14,430,622 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”), 1,576,342 of which are hereby designated as “Series A Preferred Stock” (the “Series A Preferred Stock”), 3,004,124 of which are hereby designated as “Series A-1 Preferred Stock” (the “Series A-1 Preferred Stock”), 3,186,116 of which are hereby designated as “Series B Preferred Stock” (the “Series B Preferred Stock”), and 6,664,040 of which are hereby designated as “Series C Preferred Stock” (the “Series C Preferred Stock”).
The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.
1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.
2. Voting. The holders of the Common Stock are entitled to one (1) vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Corporation’s certificate of incorporation, as may be amended from time to time (the “Certificate of
1